Aquestive Therapeutics reported second quarter 2026 revenue of $13.8 million, representing a 38% increase year-over-year but falling short of the $14.2 million analyst estimate. The company posted a GAAP net loss of $22.9 million, or $0.18 per share, which was impacted by a $11.7 million one-time loss on debt extinguishment; excluding this charge, the adjusted net loss was $11.2 million.
Key Highlights
- Successfully completed human factors validation and pharmacokinetic studies for Anaphylm, remaining on track for an NDA resubmission in the third quarter 2026.
- Manufacture and supply revenue increased 24% to $11.9 million, driven by higher Suboxone volumes and the production of 48 million total doses.
- Ended the period with $98.5 million in cash and cash equivalents, providing sufficient runway through anticipated regulatory milestones for the epinephrine prodrug platform.